Table 1.
Patient and tumor characteristics.
| Characteristics | N = 120 |
|---|---|
| Age (years), median (range) | 49 (25–72) |
| Histology | |
| IDC | 115 (96%) |
| ILC/other | 5 (4%) |
| Clinical T stage | |
| T1-2 | 79 (66%) |
| T3-4 | 41 (34%) |
| Clinical anatomic stage | |
| IIA-IIIA | 97 (81%) |
| IIIB-IIIC | 23 (19%) |
| ER status | |
| Positive | 65 (54%) |
| Negative | 55 (46%) |
| Molecular subtype | |
| Luminal (HER2-negative) | 38 (32%) |
| HER2-positive | 57 (47%) |
| Triple negative | 25 (21%) |
| NAC regimen | |
| Anthracycline and taxane based | 92 (77%) |
| Anthracycline based | 10 (8%) |
| Taxane based | 18 (15%) |
| Anti-HER2 therapy in 57 HER2-positive patients | |
| Neoadjuvant | 31 (55%) |
| Adjuvant only | 19 (33%) |
| None | 7 (12%) |
| NAC response | |
| pCR (ypT0/is ypN0) | 22 (18%) |
| Residual tumor | 98 (82%) |
| Surgery | |
| Breast-conserving surgery | 66 (55%) |
| Mastectomy | 54 (45%) |
| Recurrence | |
| Yes | 16 (13%) |
| No | 104 (87%) |
Values are n (%) unless otherwise specified. IDC: invasive ductal carcinoma; ILC: invasive lobular carcinoma; ER: estrogen receptor; NAC: neoadjuvant chemotherapy; pCR: pathologic complete response.